Patients
extrahepatic disease, tumor, melanoma, uveal melanoma, renal dysfunction
TUMOR, LIVER METASTASES, MELANOMA, UVEAL MELANOMA, DISEASE, METASTASES
Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT). Patients were excluded if tumor occupied 50% or more of the liver as assessed by CT or magnetic resonance imaging (MRI); if there was significant heart, lung, or renal dysfunction; or if the patient had a BMI above 35.